The use of a heparin removal device: A valid alternative to protamine

International Journal of Artificial Organs

Volumn 20, Issue 3, 1997, Pages 166-174

  Hendrikx, M ^a   Leunens, V ^a   Vandezande, E ^a   Wallyn, A ^a   Flameng, W ^a  

^a Department of Cardiovascular Diseases   (Belgium)

Author keywords

cardiopulmonary bypass; filter; heparin; protamine

Indexed keywords

BANDPASS FILTERS; BLOOD;

ACTIVATED CLOTTING TIME; ACTIVATED PARTIAL THROMBOPLASTIN TIME; CARDIOPULMONARY BYPASS; EXTRACORPOREAL CIRCULATION; FILTER; HEMODYNAMIC PARAMETERS; HEPARINIZATION; PROTAMINE; RED BLOOD CELL; WHITE BLOOD CELLS;

POLYSACCHARIDES;

HEPARIN; PROTAMINE;

ANIMAL EXPERIMENT; ARTICLE; CARDIOPULMONARY BYPASS; DOG; MEDICAL INSTRUMENTATION; NONHUMAN;

EID: 0030956697     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889702000308     Document Type: Article

References (34)

1. Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 1984; 17: 375-9.
2. Hirsh J. Heparin induced bleeding. Nouv Rev Fr Hematol 1984; 26: 261-6.
3. Lindblad B. Protamine sulphate: a review of its effects: hyper-sensitivity and toxicity. Eur J Vasc Surg 1989; 3: 195-201.
4. Wakefield TW, Hantler CB, Lindblad B, Whitehouse WM Jr, Stanley JC. Protamine pretreatment attenuation of hemodynamic and hematologic effects of heparin-protamine interaction. J Vasc Surg 1986; 3: 885-9.
5. Morel DR, Lowenstein E, Nguyenduy T, et al. Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep: evidence for the role of reactive oxygen metabolites following nonimmunological complement activation. Circ Res 1988; 62: 905-15.
6. Weiler JM, Freiman P, Sharath MD, et al. Serious adverse reactions to protamine sulphate: are alternatives needed? J Allergy Clin Immunol 1985; 75: 297-303.
7. Yang VC, Port FK, Kim J-S, Teng C-L, Till GO, Wakefield TW. The use of immobilised protamine in removing heparin and preventing protamine-induced complications during extracorporeal blood circulation. Anesthesiology 1991; 75: 288-97.
8. Ma X, Mohammad SF, Kim SW. Heparin binding on poly(L-lysine) immobilised surface. J Colloid Interface Sc 1991; 147: 251-61.
9. Ma X, Mohammad SF, Kim SW. Interaction of heparin with polyallylamine-immobilised surfaces. J Biomed Mat Res 1993; 27: 357-65.
10. Arnold LJ, Dagan LJ, Gutheil J, Kaplan NO. Antineoplastic activity of poly-L-lysine with some ascites tumor cells. Proc Natl Acad Sci USA 1979; 76: 3246-50.
11. Cranney J, Poulsen S, McRea J, Triolo P, Schwartz E. Three week toxicity study of a heparin removal device in dogs. Poster. 19th Annual Meeting of the Society for Biomaterials in conjunction with the 25th International Biomaterials Symposium. April 28 - May 2 1993, Birmingham, AL.
12. Fabian I, Aronson M. Polycations as possible substitutes for protamine in heparin neutralization. Thromb Research 1980; 17: 239-47.
13. Ma X, Mohammad SF, Kim SW. Heparin removal from blood using poly(L-lysine) immobilised hollow fiber. Biotech Bioeng 1992; 40: 530-6.
14. Horrow JC. Protamine: a review of its toxicity. Anesth Analg 1985; 64: 348-61.
15. Conahan TJ III, Andrews RW, MacVaugh H III. Cardiovascular effects of protamine sulphate in man. Anesth Analg 1981; 60: 33-6.
16. Jaques LB. Protamine: antagonist to heparin. Can Med Assoc J 1973; 108: 1291-7.
17. Kirklin JK, Chenoweth DE, Naftel DC, et al. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. Ann Thorac Surg 1986; 41: 193-9.
18. Morel DR, Costabella PMM, Pittet JF. Adverse cardiopulmonary effects and increased plasma thromboxane concentrations following the neutralisation of heparin with protamine in awake sheep are infusion-rate dependent. Anesthesiology 1990; 73: 415-24.
19. Degges RD, Foster ME, Dang AQ, Read RC. Pulmonary hypertensive effect of heparin and protamine interaction: evidence for thromboxane B2 release from the lung. Am J Surg 1987; 154: 696-9.
20. Lowenstein E, Zapol W. Protamine reactions, explosive mediator release, and pulmonary vasoconstriction. Anesthesiology 1990; 73: 373-5.
21. Wakefield TW, Whitehouse WM Jr, Stanley JC. Depressed cardiovascular function and altered platelet kinetics following protamine sulphate reversal of heparin activity. J Vasc Surg 1986; 1: 346-55.
22. Flahertz TJ, Craddock PR, Hammersmidt DE, Moldow CF. Effect of intravascular complement activation on granulocyte adhesiveness and distribution. Blood 1978; 51: 731-9.
23. Jacob HS, Craddock PR, Hammersmidt DE, Moldow CF. Complement-induced granulocyte aggregation. N Engl J Med 1980; 302: 789-94.
24. Chenoweth DE, Copper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass. N Engl J Med 1981; 304: 497-503.
25. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 186: 845-57.
26. Moore FD, Warner KG, Assousa S, Valeri CR, Khuri SF. The effects of complement activation during cardiopulmonary bypass. Ann Surg 1987; 208: 95-103.
27. Kutsal A, Erosy Ü, Ersoy F, Yeniay I, Bakaloglu A, Bozer Y. Complement activation during cardiopulmonary bypass J Cardiovasc Surg 1989; 30: 359-63.
28. Hammersmidt DE, Strocek DF, Bowers TK, et al. Complement activation and neutropenia occurring during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981; 81: 370-7.
29. Kirschfink M, Kovacs B, Mottaghy K. Extracorporeal circulation: In vivo and in vitro analysis of complement activation by heparin-bonded surfaces. Circulatory Shock 1993; 40: 221-6.
30. Reut R, Ertel N, Eienstein R, Gewurz H. Complement activation by interaction of polyanions and polycations: heparin-protamine induced consumption of complement. J Immunol 1975; 114: 120-4.
31. Fiedel BA, Reut R, Myhrman R, Gewurz H. Complement activation by interaction of polyanions and polycations: II precipitation and the role of IgG, C1q and C1-INH during heparin-protamine induced consumption of complement. Immunology 1976; 30: 161-9.
32. Weiler JM, Gellhaus MA, Carter JG, et al. A prospective study of the risk of an immediate adverse reaction to protamine sulphate during cardiopulmonary bypass surgery. J Allergy Clin Immunol 1990; 58: 713-9.
33. Weiss ME, Nyhan D, Peng Z, et al. Association of protamine IgG and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989; 320: 886-92.
34. Lakin JD, Blocker TJ, Strong DM, Yocum MW. Anaphylaxis to protamine sulphate mediated by a complement derived IgG antibody. J Allergy Clin Immunol 1978; 61: 102-7.